B-intervention	0	10	Aprepitant
I-intervention	11	15	plus
I-intervention	16	28	palonosetron
O	29	32	for
O	33	36	the
O	37	47	prevention
O	48	50	of
B-condition	51	64	postoperative
I-condition	65	71	nausea
I-condition	72	75	and
I-condition	76	84	vomiting
O	85	90	after
O	91	97	breast
O	98	104	cancer
O	105	112	surgery
O	112	113	:
O	114	115	a
O	116	122	double
O	123	128	blind
O	128	129	,
O	130	140	randomized
O	141	146	trial
O	146	147	.

O	148	150	To
O	151	159	evaluate
O	160	163	the
O	164	172	addition
O	173	175	of
O	176	177	a
O	178	184	fourth
O	185	195	antiemetic
O	196	208	intervention
O	209	211	in
O	212	220	patients
O	221	223	at
O	224	228	high
O	229	233	risk
O	234	237	for
O	238	251	postoperative
O	252	258	nausea
O	259	262	and
O	263	271	vomiting
O	272	273	(
O	273	277	PONV
O	277	278	)
O	278	279	.

B-eligibility	280	284	High
I-eligibility	284	285	-
I-eligibility	285	289	risk
I-eligibility	290	298	patients
I-eligibility	299	300	(
I-eligibility	300	305	Apfel
I-eligibility	306	311	score
I-eligibility	312	313	3
I-eligibility	314	316	or
I-eligibility	317	318	4
I-eligibility	318	319	)
I-eligibility	320	329	scheduled
I-eligibility	330	333	for
I-eligibility	334	344	unilateral
I-eligibility	345	355	mastectomy
O	356	360	were
O	361	369	randomly
O	370	379	allocated
O	380	382	in
O	383	386	one
O	387	389	of
O	390	393	two
O	394	400	groups
O	400	401	,
O	402	406	oral
O	407	417	aprepitant
O	418	419	(
O	419	423	oral
O	424	434	aprepitant
O	435	437	80
O	438	440	mg
O	440	441	,
O	442	453	intravenous
O	454	467	dexamethasone
O	468	469	8
O	470	472	mg
O	472	473	,
O	474	477	and
O	478	490	palonosetron
O	491	492	0
O	492	493	.
O	493	496	075
O	497	499	mg
O	499	500	)
O	501	504	and
B-control	505	509	oral
I-control	510	517	placebo
O	518	519	(
O	519	523	oral
O	524	531	placebo
O	531	532	,
O	533	544	intravenous
O	545	558	dexamethasone
O	559	560	4
O	561	563	mg
O	563	564	,
O	565	568	and
O	569	581	palonosetron
O	582	583	0
O	583	584	.
O	584	587	075
O	588	590	mg
O	590	591	)
O	591	592	.

O	593	601	Patients
O	602	605	and
O	606	616	caregivers
O	617	621	were
O	622	629	blinded
O	630	632	to
O	633	636	the
O	637	642	group
O	643	654	assignments
O	654	655	.

O	656	659	The
O	660	667	primary
O	668	676	efficacy
O	677	686	endpoints
O	687	695	included
O	696	699	the
B-outcome-Measure	700	709	incidence
I-outcome-Measure	710	712	of
I-outcome-Measure	713	719	nausea
I-outcome-Measure	720	723	and
I-outcome-Measure	724	732	vomiting
O	732	733	,
O	734	737	and
O	738	741	the
O	742	751	secondary
O	752	761	endpoints
O	762	770	included
B-outcome-Measure	771	774	use
I-outcome-Measure	775	777	of
I-outcome-Measure	778	784	rescue
I-outcome-Measure	785	796	antiemetics
I-outcome-Measure	797	803	during
I-outcome-Measure	804	805	a
I-outcome-Measure	806	808	48
I-outcome-Measure	808	809	-
I-outcome-Measure	809	813	hour
I-outcome-Measure	814	827	postoperative
I-outcome-Measure	828	834	period
O	834	835	.

O	836	850	ClinicalTrials
O	850	851	.
O	852	855	gov
O	855	856	:
O	857	868	NCT02431286
O	868	869	.

B-total-participants	870	873	One
I-total-participants	874	881	hundred
O	882	890	patients
O	891	895	were
O	896	904	enrolled
O	905	907	in
O	908	912	this
O	913	918	study
O	919	922	and
B-total-participants	923	925	91
O	926	930	were
O	931	939	analyzed
O	939	940	,
B-intervention-participants	941	943	48
O	944	946	in
O	947	952	group
O	953	954	A
O	955	958	and
B-control-participants	959	961	43
O	962	964	in
O	965	970	group
O	971	972	P
O	972	973	.

O	974	976	No
O	977	984	patient
O	985	994	presented
O	995	999	with
O	1000	1006	nausea
O	1007	1009	or
O	1010	1018	vomiting
O	1019	1021	in
O	1022	1025	the
O	1026	1031	first
O	1032	1033	2
O	1034	1039	hours
O	1040	1045	after
O	1046	1053	surgery
O	1053	1054	.

O	1055	1059	From
O	1060	1063	the
B-outcome	1064	1067	2nd
I-outcome	1068	1070	to
I-outcome	1071	1074	the
I-outcome	1075	1078	6th
I-outcome	1079	1083	hour
O	1083	1084	,
O	1085	1088	the
B-outcome	1089	1098	incidence
I-outcome	1099	1101	of
I-outcome	1102	1106	PONV
O	1107	1110	was
B-iv-bin-percent	1111	1112	8
I-iv-bin-percent	1112	1113	.
I-iv-bin-percent	1113	1115	33
I-iv-bin-percent	1115	1116	%
O	1117	1119	in
O	1120	1125	group
O	1126	1127	A
O	1128	1131	and
B-cv-bin-percent	1132	1133	9
I-cv-bin-percent	1133	1134	.
I-cv-bin-percent	1134	1136	30
I-cv-bin-percent	1136	1137	%
O	1138	1140	in
O	1141	1146	group
O	1147	1148	P
O	1148	1149	.

O	1150	1152	In
O	1153	1156	the
B-outcome	1157	1162	first
I-outcome	1163	1165	24
I-outcome	1166	1171	hours
O	1171	1172	,
O	1173	1176	the
B-outcome	1177	1186	incidence
I-outcome	1187	1189	of
I-outcome	1190	1194	PONV
O	1195	1198	was
B-iv-bin-percent	1199	1201	27
I-iv-bin-percent	1201	1202	.
I-iv-bin-percent	1202	1204	08
I-iv-bin-percent	1204	1205	%
O	1206	1208	in
O	1209	1212	the
O	1213	1218	group
O	1219	1220	A
O	1221	1224	and
B-cv-bin-percent	1225	1227	20
I-cv-bin-percent	1227	1228	.
I-cv-bin-percent	1228	1230	93
I-cv-bin-percent	1230	1231	%
O	1232	1234	in
O	1235	1240	group
O	1241	1242	P
O	1242	1243	.

O	1244	1248	From
O	1249	1252	the
B-outcome	1253	1257	24th
I-outcome	1258	1260	to
I-outcome	1261	1264	the
I-outcome	1265	1269	48th
I-outcome	1270	1274	hour
O	1274	1275	,
O	1276	1279	the
B-outcome	1280	1289	incidence
I-outcome	1290	1292	of
I-outcome	1293	1297	PONV
O	1298	1301	was
B-iv-bin-percent	1302	1303	8
I-iv-bin-percent	1303	1304	.
I-iv-bin-percent	1304	1306	33
I-iv-bin-percent	1306	1307	%
O	1308	1310	in
O	1311	1316	group
O	1317	1318	A
O	1319	1322	and
B-cv-bin-percent	1323	1325	13
I-cv-bin-percent	1325	1326	.
I-cv-bin-percent	1326	1328	95
I-cv-bin-percent	1328	1329	%
O	1330	1332	in
O	1333	1338	group
O	1339	1340	P
O	1340	1341	.

O	1342	1347	There
O	1348	1352	were
O	1353	1355	no
O	1356	1369	statistically
O	1370	1381	significant
O	1382	1393	differences
O	1394	1396	in
B-outcome	1397	1401	PONV
O	1402	1409	between
O	1410	1416	groups
O	1416	1417	.

O	1418	1421	The
O	1422	1430	addition
O	1431	1433	of
O	1434	1444	aprepitant
O	1445	1447	as
O	1448	1449	a
O	1450	1455	third
O	1456	1466	antiemetic
O	1467	1475	resulted
O	1476	1478	in
O	1479	1481	no
O	1482	1493	significant
O	1494	1503	reduction
O	1504	1506	in
O	1507	1510	the
O	1511	1520	incidence
O	1521	1523	of
O	1524	1528	PONV
O	1529	1531	in
O	1532	1536	this
O	1537	1547	population
O	1547	1548	.

O	1549	1556	However
O	1556	1557	,
O	1558	1561	the
O	1562	1571	incidence
O	1572	1574	of
O	1575	1579	PONV
O	1580	1583	was
O	1584	1591	reduced
O	1592	1594	in
O	1595	1603	relation
O	1604	1606	to
O	1607	1610	the
O	1611	1618	general
O	1619	1629	population
O	1629	1630	.
